Diabetes Mellitus

• FDA label_change · 2021-07-15
  FDA Approved: GVOKE HYPOPEN 0.5 MG AUTO-INJECTOR — Supplemental Application (Xeris Pharmaceuticals, Inc.)

  FDA approved a supplemental application for GVOKE HYPOPEN 0.5 mg auto-injector (glucagon injection, solution) by Xeris Pharmaceuticals, upda…

• FDA label_change · 2019-11-15
  FDA Approved: NOVOLIN 70/30 — Supplemental Application (Novo Nordisk)

  FDA approved a supplemental application for NOVOLIN 70/30 (human insulin) submitted by Novo Nordisk; the snippet does not specify the exact …

• FDA label_change · 2019-11-15
  FDA Approved: TRESIBA — Supplemental Application (Novo Nordisk)

  FDA approved a supplemental application for Tresiba (insulin degludec) filed by Novo Nordisk.

• EMA label_change · 2018-03-23
  Colour change for insulin injection Fiasp to avoid mix ups with Tresiba

  The EMA announces a colour change for the insulin product Fiasp to help prevent mix-ups with Tresiba, involving visual identifier updates.

• FDA label_change · 2017-01-06
  FDA Approved: HUMULIN 70/30 — Supplemental Application (Eli Lilly and Company)

  The FDA approved a supplemental application for Humulin 70/30 (insulin human) from Eli Lilly and Company.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA label_change · 2007-09-25
  FDA Approved: SYMLINPEN — Supplemental Application (AstraZeneca Pharmaceuticals LP)

  The FDA approved a supplemental labeling application for SymlinPen (pramlintide acetate) submitted by AstraZeneca Pharmaceuticals LP. This a…